MLN4924: a novel first-in-class inhibitor of NEDD8-activating enzyme for cancer therapy

Author： Nawrocki Steffan T Griffin Patrick Kelly Kevin R Carew Jennifer S

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.21, Iss.10, 2012-10, pp. : 1563-1573

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Negative Regulation of NEDD8 Conjugation Pathway by Novel Molecules and Agents for Anticancer Therapy

Current Pharmaceutical Design, Vol. 19, Iss. 22, 2013-07 ,pp. : 4131-4139

Bentham Science Publishers

Access to resources Recommend Favorite

NEDD4: A Promising Target for Cancer Therapy

Current Cancer Drug Targets, Vol. 14, Iss. 6, 2014-07 ,pp. : 549-556

Bentham Science Publishers

Access to resources Recommend Favorite

The Effect of First-in-Class Small Molecule RhoA Inhibitor, HL07, on the Phenylephrine-induced Artery Contraction

Current Pharmaceutical Design, Vol. 18, Iss. 27, 2012-09 ,pp. : 4258-4264

Bentham Science Publishers

Access to resources Recommend Favorite

Immunokinases, a Novel Class of Immunotherapeutics for Targeted Cancer Therapy

Current Pharmaceutical Design, Vol. 15, Iss. 23, 2009-08 ,pp. : 2693-2699

Bentham Science Publishers

Access to resources Recommend Favorite

Aliskiren: first-in-class antihypertensive a big act to follow

Inpharma, Vol. 1, Iss. 1542, 2006-01 ,pp. : 6-6

Adis International

Access to resources Recommend Favorite